Provided by Tiger Fintech (Singapore) Pte. Ltd.

Monkeypox Concept

1,490.89
+14.160.96%
Number of Gainers:2
Number of Losers:9
Number of Flat:- -
PE:- -
High:1,516.24
Open:1,476.55
Low:1,468.84
Close:1,476.73
Loading ...

GeoVax Labs Inc. Conducted Annual Stockholders Meeting

Reuters
·
9 hours ago

Aethlon Medical Approves Reverse Stock Split Plan

TIPRANKS
·
Yesterday

Aethlon Medical Inc. Announces 1-for-8 Reverse Stock Split Effective June 9, 2025

Reuters
·
Yesterday

Emergent BioSolutions teams up with Victoria’s Voice Foundation

TIPRANKS
·
Yesterday

A New Shot Prevents HIV and Breathes New Life Into a Stagnant Biotech -- Heard on the Street -- WSJ

Dow Jones
·
Yesterday

Gilead Sciences’ Oncology Advancements: Trodelvy’s Potential to Boost Stock Value

TIPRANKS
·
Yesterday

Daniel Patrick O'Day, Chairman & CEO, Reports Disposal of Common Shares in Gilead Sciences Inc

Reuters
·
03 Jun

BRIEF-Viatris Announces Positive Top-Line Results From Phase 3 Lynx-2 Trial Of Mr-142 In Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Reuters
·
02 Jun

Viatris Inc. Announces Breakthrough Phase 3 Trial Results for MR-142, Pioneering Treatment for Night Driving Impairment in Keratorefractive Patients

Reuters
·
02 Jun

Viatris Announces Positive Top-Line Results From Phase 3 Lynx-2 Trial of Mr-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

THOMSON REUTERS
·
02 Jun

Viatris Inc - Results Show Functional Benefit in Treating Night Driving Impairment

THOMSON REUTERS
·
02 Jun

Viatris Inc - Mr-142 Achieved Primary Endpoint of ≥15-Letter Gain in Mlcva

THOMSON REUTERS
·
02 Jun

Viatris Inc - No Evidence of Tachyphylaxis Observed Over 6-Week Period

THOMSON REUTERS
·
02 Jun

Gilead Sciences (GILD) Gets a Hold from Truist Financial

TIPRANKS
·
02 Jun

Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV) and Gilead Sciences (GILD)

TIPRANKS
·
02 Jun

Gilead’s Kite announces real-world safety, effectiveness of Yescarta

TIPRANKS
·
02 Jun

Gilead Sciences Reveals Promising Results of Yescarta® in Outpatient Care for Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025

Reuters
·
01 Jun

Gilead's CAR-T cell therapy shows promise in deadly brain cancer

Reuters
·
01 Jun

Gilead Sciences Unveils Promising Phase 3 Results: Trodelvy Plus Keytruda Reduces Disease Progression Risk by 35% in Metastatic Triple-Negative Breast Cancer

Reuters
·
31 May

Keytruda® (Pembrolizumab) Plus Trodelvy® (Sacituzumab Govitecan-Hziy) Reduced Risk of Disease Progression or Death by 35% Versus Keytruda Plus Chemotherapy in First-Line Pd-L1+ Metastatic Triple-Negative Breast Cancer (Tnbc)

THOMSON REUTERS
·
31 May